



CIN : L99999MH1951PLC008485

Regd. Office : A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India

Tel : +91-22-67980888 , ● Fax : +91-22-67980899 , ● Email : contact@dil.net , ● Website: www.dil.net

Ref: DIL/BSE/2019-20/F.No.:49

August 8, 2019

Corporate Relations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Dear Sir,

Sub.: Intimation of Investor Presentation for August 2019

Ref: Scrip Code: 506414

Further to our intimation dated August 5, 2019 regarding approval of Unaudited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter ended June 30, 2019, we hereby enclose a copy of Investor Presentation for August 2019.

The said Investor Presentation is also available on Company's website www.dil.net



Kindly take the same on records.

Thanking you,

Yours faithfully,
for **DIL LIMITED**

Srikant N Sharma
Company Secretary
CS Membership No: F3617
A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610

Encl: As above



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **DIL Limited**. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Fermenta Biotech: Q1 Financial Highlights




Fermenta Biotech Limited


Revenue* (Rs. Crs)



EBITDA* (Rs. Crs)



PAT^ (Rs. Crs)



Business Update:

- In Q1 FY20, Company has taken a planned shutdown of Dahej plant to carry out major repairs and maintenance work and de-bottlenecking programme
- The shutdown was for nearly a month and was completed on May 29, 2019
- Post completion of this de-bottlenecking programme, the production capacity has increased by approximately 15%
- The de-bottlenecking programme is part of the overall strategy of FBL to increase the production capacity

*Includes Other Income

^ PAT before share of profit / loss from associates & JV's and Minority Interest

Fermenta Biotech: Profit and Loss




Fermenta Biotech Limited

Particulars (Rs. Crs)	Q1 FY20	Q1 FY19	Y-o-Y
Revenue	77.0	76.5	0.7%
Other Income	3.1	3.2	
Total Revenue	80.1	79.7	0.5%
Raw Material	19.8	20.3	
Employee Expenses	12.9	9.0	
Other Expenses	20.5	21.7	
EBITDA	26.9	28.7	-6.2%
EBITDA Margin %	33.6%	35.9%	
Depreciation	3.4	1.8	
EBIT	23.5	26.9	-12.6%
EBIT Margin %	29.4%	33.7%	
Finance Cost	1.1	0.5	
PBT	22.4	26.4	-15.1%
Tax	6.1	5.3	
PAT	16.3	21.1	-22.9%
PAT Margin %	20.3%	26.5%	


- Revenue from Vitamin D3 for Human use contributed 45% to overall revenue as compared to 29% in Q1 FY19
- Revenue from Vitamin D3 for Animal Feed use contributed 41% to overall revenue as compared to 47% in Q1 FY19
- The prices of Vitamin D3 for Animal Feed have shown weaker tone as compared to earlier quarters

Q1 FY20 Consolidated Financial Highlights (YoY)


Revenue* (Rs. Crs)



EBITDA* (Rs. Crs)



PAT^ (Rs. Crs)




*Includes Other Income

On Consolidated Basis ^ PAT before share of profit / loss from associates & JV's and Minority Interest

Consolidated Profit and Loss

Particulars (Rs. Crs)	Q1 FY20	Q1 FY19	YoY
Revenue	81.2	80.1	1.3%
Other Income	2.9	3.3	
Total Revenue	84.1	83.5	0.8%
Raw Material	19.8	20.3	
Employee Expenses	14.0	10.5	
Other Expenses	22.9	23.4	
EBITDA	27.4	29.2	-6.0%
EBITDA Margin %	32.6%	35.0%	
Depreciation	3.5	2.8	
EBIT	23.9	26.4	-9.2%
EBIT Margin %	28.5%	31.6%	
Finance Cost	4.9	4.4	
PBT	19.0	22.0	-13.5%
Tax	4.9	5.3	
PAT	14.1	16.7	-15.7%
PAT Margin %	16.7%	20.0%	
Share of profit /(loss) of JV's and Associates	0.0	-0.1	
PAT after share of profit / (loss) of JV's and Associates	14.1	16.6	-15.2%
Minority Interest	0.0	0.0	
PAT after MI	14.1	16.6	-15.2%
EPS (in Rs.)	14.2	16.6	

Six Decades of History





DIL Ltd. through its subsidiary is primarily engaged in the business of Pharmaceuticals and Integrated Biotechnology

1 Fermenta Biotech (91.2% Subsidiary)




- A company focused on research, development and product delivery in pharmaceutical and integrated biotechnology
- Only manufacturer of Vitamin D3 in India; amongst few leading producers in the world

2 Assets


- **Thane One** – ~200,000 sq ft. leasable area, which is currently 100% occupied + has an additional **freehold land** of ~5.5 acres in Thane
- **Ceejay House** – ~10,000 sq ft. area leased
- ~45 acres of **Freehold Land** in Takawe, Pune



API




Integrated Biotechnology



Vitamin D3

Through Merger of FBL with DIL



Contours of the Merger

Merger Consideration

- There is no cash consideration
- 100 Equity shares of DIL of Rs. 10 each fully paid up for every 1,006 equity shares of FBL of Rs. 10 each fully paid up
- Subject to members approval, the Board of Directors of DIL Ltd at its meeting held on June 18, 2018 approved:
 - Split / sub-division of equity shares from face value of Rs. 10 each to face value of Rs. 5 each
 - Issue of Bonus equity shares in proportion of 1:1, having face value of Rs. 5 each
 - Accordingly, the number of shares to be issued to the FBL shareholders will undergo change i.e. 100 equity shares of DIL of Rs. 5 each fully paid up for every 251 equity shares of FBL of Rs. 10 each fully paid up

Category	Existing Shareholding	Post Merger Shareholding
Promoters	62.59%	58.93%
Public	37.41%	41.07%
Total	100.00%	100.00%

Current Status:

- Approval from Shareholders and Creditors received
- Awaiting final order from NCLT

Fermenta Biotech (91.2 % Subsidiary)

- A company focused on research, development and product delivery in biotechnology as well as pharmaceutical and environmental solutions
- Only manufacturer of Vitamin D3 in India; amongst few leading producers in the world

Assets

- Thane One
- Ceejay House
- Land in Takawe, Pune

Going Forward

Focus on Fermenta

- Focused towards expanding the product portfolio of Fermenta Biotech
- Positioning ourselves as Nutrition Supplement Business


Assets

- Leverage on available real estate assets for the use of expansion and growth within Fermenta Biotech


Fermenta's Portfolio Outlook



Fermenta Biotech Limited




Excellence in Operations




The Emerging Nutraceuticals Market



Global (USD Billion)



Domestic (USD Billion)




Nutraceutical Market Size

Key Drivers

- Well developed/ Matured market
- Well defined value chain
- Retail/Consumer driven approach
- Ascertained awareness

- Large population with increasing disposable income, emerging market
- Favourable government policies for food fortification


Consistent Dividend Paying




*About Fermenta
Biotech Limited*



Three Decades of Fermenta...



..progress over the Last Decade



Experienced Board of Directors

Mr. Sanjay Buch

Chairman

**Mr. Satish
Varma**

Managing Director

**Ms. Anupama
Datla Desai**

Executive Director


Mr. Krishna Datla

Non- Executive Director

**Dr. Gopakumar
Nair**

Independent Director

Vitamin D3



Applications

Human Health



Pharmaceuticals



Dietary Supplements



Food

Animal Health




Veterinary



Feed

Vitamin D – Important Facts to Know



Vitamin D3 – Our Proprietary Technology


Pioneering

Use of proprietary technology to manufacture Vitamin D3 API in India



Scale

It is among the top three producers of Vitamin D3 API in the world




Integrated

Fully integrated Vitamin D3 API manufacturer benefiting from superior quality and cost effectiveness



Natural

The cholesterol used, is obtained from sheep wool from TSE/BSE risk free countries



Unique

One of three CEP-certified companies worldwide; its products and manufacturing facilities have been certified by various international regulatory bodies



Knowledge Capital

It has been manufacturing Vitamin D3 for over 50 years with a base of over 300+ customers



One Stop Shop

It manufactures Vitamin D3 for various applications (human and veterinary healthcare, Animal Feed)



Standardized

Manufacturing facilities are benchmarked with the best global standards, backed by dedicated professionals and accreditations from a large number of global regulatory agencies



Global Presence

- Nascent and Mature business mix
- **Globally Recognized Plants** for key products
- Proprietary IPR-driven research
- Multi-decadal **Experience**
- Competent and experienced **Human Capital**
- Governance focus
- Global quality **Certifications**
- **50 countries** across the world



Niche Presence

- Growing number of Multi-year accounts
- Among the **Worlds Largest D3 Makers** and **Leading Phenyramidol Manufacturer**
- Among top pioneering companies to **introduce enzymatic antibiotics manufacturing technology**
- Among few non-European companies with a **CEP accreditation** by EQDM for Vitamin D3



Financial Strength

- **Healthy Balance Sheet**
- Profitable **Growth**
- **Low cost borrowings** due to significant exports



- For over 25 years, Fermenta Biotech Ltd. (FBL) has been dedicated towards manufacturing specialty APIs and Bio-Catalysts.
- The Company is a trusted and reliable source of specialty pharmaceutical products worldwide

Phenyramidol HCl

Phenyramidol Hydrochloride is an unique API. A potent muscle relaxant with concomitant analgesic effect

FBL has been a pioneer in reviving Phenyramidol HCl as an API and has successfully marketed the product in Turkey and India. The formulation of Phenyramidol grew exponentially in Turkey

Silicon Powder (Activated Dimethicone Powder)

Manufacturing of Silicon Powder (Activated Dimethicone Powder) was a conscious effort by FBL to offer a product that could replace simethicone oil in anti-flatulent oral formulations.

Replacement by silicon powder has helped enhance properties of powdered anti-flatulent oral formulations. Endorsed by one of the most popular pharma brands in Turkey, the product is presently being used in their anti-flatulent and digestive enzyme formulations.



- FBL is a leader in providing immobilized enzymes and enzyme technologies, and proprietary immobilization platforms
- Products are supplied to Sectors like Pharmaceutical, Fine Chemicals to Bioplastics, Cosmetics etc
- Our enzyme technologies for the synthesis of beta lactams and cephalosporin antibiotics offer unique advantages, which are not only scalable but also enable competitive transformation
- Some of the flagship enzyme products range from the classical "white enzyme", Penicillin G amidase-(PA 850) to the more advanced enzyme variants like Novel Penicillin G Amidase and CALB Lipase (CALB10000)
- We also offer enzyme immobilization optimization and supply services of various scale upto multi-ton commercial quantities
- Our special microorganisms, enzymes and platform technologies provide unique advantages in waste water treatment and management

“
Driven by the
Discover,
Develop &
Deliver
philosophy”



Modern, fully equipped, DSIR approved Research & Development facility complimented by highly skilled and committed scientists.



Providing **Integrated Solutions**, processes and products for Biotech and Active Pharmaceutical Ingredients (API)



API R&D, combined with expertise on photochemistry, chromatography and multi-step process development skills



Biotech R&D has got wide experience in the areas of bacterial fermentation, enzyme expression, immobilization platforms and process development in various enzymatic applications





Enzyme technology platform is aimed at helping companies become environmentally responsible and sustainable (Green Chemistry)



Shifted to New R&D Centre of 15,000 sq. ft


Geographical Presence – Manufacturing & Clientele

Manufacturing & Operating Locations




Supplying More than **300 Customers** both Domestic & International

Revenue – Breakup – FY19



*Acquired Land at Sayakha for future expansion of 40,000 Sq.Mt.

Manufacturing Units – Kullu, Himachal Pradesh



- ✓ Set up the Biotech plant in 1987 to manufacture Penicillin G Amidase and Penicillin G Acylase enzyme and emerged as the leader in enzyme technologies for beta lactam in India
- ✓ Set up Bulk Drug division in 2004 to manufacture various APIs like Vitamin D3, Phenyramidol HCl (Fenyramidol) and Silicon Powder (Activated Dimethicone Powder)
- ✓ Facility is cGMP compliant, supplies its products across the globe

Manufacturing Units – Dahej Gujarat





✓ Established a green field manufacturing facility at Dahej SEZ Ltd. in 2011 to cater to the growing international market

✓ Site has dedicated manufacturing blocks for API's/Intermediates


✓ Strict adherence to Safety, Health & Environment (SHE) policy

Both the manufacturing units are registered with US FDA "Food Facility Registration Module (FFRM)"

Our Accreditations



Product specific and Site specific




We have been **Investing in Technology** for optimizing process parameters, moderating costs and increasing efficiency

Fermenta – Historical Performance




Fermenta Biotech Limited


Revenue^ (Rs. Crs)




EBITDA^ (Rs. Crs)




PAT (Rs. Crs)




Cash PAT (Rs. Crs)



EBITDA (%)



PAT (%)



*As per IND-AS

^Includes Other Income

Fermenta Biotech: Profit and Loss



Fermenta Biotech Limited

Particulars (Rs. Crs)	FY19	FY18	Y-o-Y
Revenue	389.3	291.7	33.4%
Other Income	12.1	8.5	
Total Revenue	401.3	300.2	33.7%
Raw Material	92.3	79.8	
Employee Expenses	47.5	34.1	
Other Expenses	102.0	83.1	
EBITDA	159.5	103.2	54.6%
EBITDA Margin %	39.8%	34.4%	
Depreciation	8.1	7.7	
EBIT	151.4	95.5	58.6%
EBIT Margin %	37.7%	31.8%	
Finance Cost	4.7	3.0	
PBT	146.7	92.5	58.6%
Tax	33.7	20.4	
PAT	113.00	72.1	56.8%
PAT Margin %	28.15%	24.01%	
EPS	63.8	40.7	

- Vitamin D3 for Human use which is 33.6% of overall revenues has witnessed a growth of 54.3% in FY19 on a YoY basis
- Vitamin D3 for Animal Feed use which is 49.8% of overall revenues has witnessed a growth of 30.2% in FY19 on a YoY basis
- Enzymes manufacturing business revenue growth at 140.6% from Rs.5.7 Crores in FY18 to Rs.13.8 Crores in FY19 which is a very highly scalable business once it achieves an optimum scale/size

Fermenta Biotech - Balance Sheet



Fermenta Biotech Limited

EQUITY AND LIABILITIES	Mar-19	Mar-18	ASSETS	Mar-19	Mar-18
Equity			Non-current assets		
Equity Share capital	17.7	17.7	Property, plant and equipment	78.0	74.6
Non Controlling Interest			Capital work-in-progress	20.7	2.5
Other equity	267.8	155.0	Intangible assets	2.3	2.1
Sub-total - Shareholders' funds	285.6	172.7	Intangible Assets Under Development	0.9	1.0
			Investment in Subsidiaries & associates	0.4	0.4
LIABILITIES			Financial assets		
Non-current liabilities			Investments	0.0	0.0
Financial liabilities			Loans	0.3	0.1
Borrowings	8.1	3.4	Other financial assets	4.6	4.3
Provisions	4.4	2.0	Other non-current assets	28.1	4.5
Deferred tax liabilities (net)	3.7	2.2	Non-Current Tax Assets	0.0	0.1
Sub-total - Non-current liabilities	16.2	7.6	Sub-total - Non-Current Assets	135.2	89.5
Current liabilities			Current assets		
Financial liabilities			Inventories	87.7	51.2
Borrowings	53.7	24.1	Financial assets		
Trade payables	41.2	38.9	Trade receivables	65.7	68.6
Other financial liabilities	25.7	14.4	Cash and cash equivalents	39.2	21.2
Other current liabilities	2.5	4.6	Bank balances other than Cash and Cash equivalents	50.2	9.3
Provisions	0.4	0.3	Loans	11.5	0.0
Current tax liabilities (net)	5.1	3.8	Other financial assets	2.3	0.2
Sub-total - Current liabilities	128.6	86.1	Other current assets	38.6	26.2
			Sub-total - Current Assets	295.2	176.8
			Assets Classified as held for Sale		
TOTAL - EQUITY AND LIABILITIES	430.4	266.3	TOTAL - ASSETS	430.4	266.3

Strong Credit Rating of CARE A- for Long Term and CARE A2 for Short Term Loans with “Stable” Outlook

A modern office lobby with a patterned carpet, black leather sofas, and a glass coffee table. The background features a wall with the 'Thane one' logo and large glass windows.

*About DIL
Limited*

Thane
one

Experienced Board of Directors

Mr. Sanjay Buch

Chairman (Non - Executive
and Independent)

Mr. Krishna Datla

Managing Director

**Mr. Gopakumar
Nair**

Non - Executive and
Independent Director

**Ms. Rajeshwari
Datla**

Non - Executive Director


Mr. Satish Varma

Non - Executive Director

Mr. Vinayak Hajare

Non - Executive and
Independent Director

Thane One – Corporate Business IT Park



- Strategically located site off the Eastern Express Highway with easy access from all parts of Mumbai, Greater Mumbai and Thane by multiple modes of transport



- Environmentally conscious complex with a Green ambience built to **LEED PLATINUM** standards



- Car Parking with provision of charging points for electric cars & car poolers parking



- Sewage and Effluent Treatment Plant for treating and reusing water



- VAASTU Compliant



- ThaneOne awarded the "**Best Office Architecture 2013**" at Asia Pacific Property Awards, Malaysia

Standalone Profit & Loss



Particulars (Rs. Crs)	Q1FY20	Q1FY19	YoY	FY19	FY18	YoY
Revenue from Operations (Net of Excise)	5.4	4.5	18.2%	19.4	12.5	54.7%
Other Income	0.1	0.1		0.3	0.4	
Total Revenue	5.4	4.6	16.9%	19.7	12.9	52.7%
Employee Cost	1.1	1.5		5.7	5.8	
Provision for impairment of non current investments & financials asset in associates/ Joint venture	-	-		9.0	6.0	
Other Expenses	2.7	2.6		10.9	10.1	
EBITDA	1.6	0.5	-242.9%	-5.9	-9.0	34.4%
EBITDA Margin	30.1%	10.3%		-30.0%	-69.9%	
Depreciation	0.9	1.0		3.8	3.8	
EBIT	0.7	-0.5	228.2%	-9.7	-12.8	24.5%
EBIT Margin	12.8%	-11.7%		-49.2%	-99.6%	
Finance Cost	4.1	3.9		16.0	10.6	
Exceptional Item (Gain) / Loss	-	-		-	-	
Profit before Tax	-3.4	-4.4	22.3%	-25.6	-23.5	-9.3%
PBT Margin	-63.5%	-95.5%		-130.4%	-182.1%	
Tax	-1.2	0		-23.0	0.7	
PAT	-2.2	-4.4	49.5%	-2.67	-24.15	88.9%
PAT Margin %	-41.3%	-95.5%		-13.6%	-187.4%	

Standalone Balance Sheet

EQUITY AND LIABILITIES (Rs in crores)	Mar-19	Mar-18
Equity		
Equity Share capital	4.6	2.3
Other equity	55.3	62.4
Sub-total - Shareholders' funds	59.8	64.7
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Borrowings	127.1	132.0
Other financial liabilities	3.5	5.3
Provisions	1.9	0.7
Other non-current liabilities	8.7	1.7
Sub-total - Non-current liabilities	141.2	139.8
Current liabilities		
Financial liabilities		
Borrowings	6.5	5.7
Trade payables	2.7	1.8
Other financial liabilities	16.8	9.0
Other current liabilities	6.0	1.4
Provisions	0.2	0.2
Sub-total - Current liabilities	32.2	18.1
TOTAL - EQUITY AND LIABILITIES	233.2	222.6

ASSETS (Rs. In Crores)	Mar-19	Mar-18
Non-current assets		
Property, plant and equipment	10.8	11.8
Other intangible assets	0.0	0.0
Investment Property	81.8	84.1
Investment in Associates	-	7.0
Investment in Subsidiaries	100.3	100.3
Financial assets		
Investments	0.6	0.1
Loans	0.0	0.3
Share Application Money	6.0	9.1
Other financial assets	1.8	2.2
Deffered Tax Asset	23.0	-
Non-current tax assets	3.3	1.0
Other non-current assets	1.7	1.6
Sub-total - Non-Current Assets	229.2	217.5
Current assets		
Financial assets		
Investments	1.1	1.1
Trade receivables	0.3	0.3
Cash and cash equivalents	1.1	1.3
Bank balances other than Cash and Cash equivalents	0.2	0.2
Loans	0.3	0.1
Other financial assets	0.3	0.7
Other current assets	0.8	1.4
Sub-total - Current Assets	4.1	5.1
Assets Classified as held for Sale		
TOTAL - ASSETS	233.2	222.6




*Performance
Highlights*


DIL Limited – Historical Performance




Revenue (Rs. Crs)




EBITDA (Rs. Crs)




PAT^ (Rs. Crs)




Cash PAT^ (Rs. Crs)



EBITDA (%)



PAT^ (%)



Consolidated Profit and Loss

Particulars (Rs. Crs)	FY19	FY18	YoY
Revenue	404.7	302.7	33.7%
Other Income	12.4	8.9	
Total Revenue	417.0	311.6	33.8%
Raw Material	92.3	79.8	
Employee Expenses	53.2	39.8	
Other Expenses	110.4	90.0	
EBITDA	161.2	102.0	58.1%
EBITDA Margin %	38.7%	32.7%	
Depreciation	11.9	12.4	
EBIT	149.4	89.6	66.7%
EBIT Margin %	35.8%	28.8%	
Finance Cost	20.7	13.6	
PBT	128.7	76.0	69.4%
Tax	10.8	21.1	
PAT	117.9	54.8	115.0%
PAT Margin %	28.3%	17.6%	
Share of profit /(loss) of JV's and Associates	-0.4	-8.5	
PAT after share of profit / (loss) of JV's and Associates	117.47	46.34	153.5%
Minority Interest	-7.1	-12.6	
PAT after MI	110.36	33.71	227.3%
EPS (in Rs.)	120.31	36.75	


Consolidated Balance Sheet

EQUITY AND LIABILITIES	Mar-19	Mar-18
Equity		
Equity Share capital	4.6	2.3
Non Controlling Interest	18.1	11.0
Other equity	227.9	122.2
Sub-total - Shareholders' funds	250.6	135.4
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Borrowings	135.2	135.4
Other financial liabilities	1.9	3.7
Provisions	6.3	2.7
Deferred tax liabilities (net)	3.7	2.2
Other non-current liabilities	1.3	1.7
Sub-total - Non-current liabilities	148.4	145.7
Current liabilities		
Financial liabilities		
Borrowings	60.2	29.9
Trade payables	42.7	40.1
Other financial liabilities	42.5	23.3
Other current liabilities	4.9	6.1
Provisions	0.5	0.5
Current tax liabilities (net)	5.1	3.8
Sub-total - Current liabilities	156.0	103.6
TOTAL - EQUITY AND LIABILITIES	554.9	384.6

ASSETS	Mar-19	Mar-18
Non-current assets		
Property, plant and equipment	97.3	90.6
Capital work-in-progress	20.7	2.5
Other intangible assets	2.3	2.1
Intangible Assets Under Development	0.9	1.0
Investment in Subsidiaries & associates		1.2
Goodwill	4.1	4.1
Investment Property	73.8	80.5
Financial assets		
Investments	0.6	0.1
Loans	0.3	0.4
Share Application Money	6.0	7.9
Other financial assets	4.6	4.8
Other non-current assets	22.4	6.0
Deferred Tax Assets	23.0	
Non Current tax assets (net)	3.3	1.1
Sub-total - Non-Current Assets	259.3	201.2
Current assets		
Inventories	87.7	51.2
Financial assets		
Investments	1.1	1.1
Trade receivables	65.5	68.7
Cash and cash equivalents	40.8	32.4
Bank balances other than Cash and Cash equivalents	50.4	0.2
Loans	11.8	0.1
Other financial assets	2.6	0.9
Other current assets	35.7	27.7
Sub-total - Current Assets	295.6	182.3
Assets Classified as held for Sale		
TOTAL - ASSETS	554.9	384.6

Debt Break-up as on 31st March 2019

Rs. Crores



Status of Non-core Investments

Associates / Joint Venture	Status
Agastya Films LLP (Joint Venture)	Exited the Joint Venture as on 1 st January 2019
Zela Wellness Pvt Ltd (Associate)	No more an associate company post reduction of stake from 1 st January 2019
Health & Wellness Pvt Ltd (Associate)	All investments provided for as on 31 st March 2019 financials

Our Association with Vitamin Angels





PROUD SUPPORTER

- A non-profit organization providing life changing vitamins to populations in need—specifically pregnant women, new mothers, and children under five.
- Vitamin Angels works to reach underserved communities in partnership with over **700 NGOs** in more than **74 countries** around the world. It reaches over **61 million** women and children for delivering vitamin solutions.
- Last year, our support allowed Vitamin Angels to reach **40,000 additional mothers and children.**

Our Awareness Initiative: Vitamin D Guru



Fermenta Biotech Limited



An Innovative public awareness portal dedicated to spreading awareness about Vitamin D, its intake and benefits.

Aims to build a community of Vitamin D conscious health users who can share their experiences with others

Our endeavour to unlock access to millions of internet users and turn them into healthy and enriched human beings to maintain an optimum level of Vitamin D

Our Association with NAB



Corneal Transplant (Keratoplasty)



Squint (Strabismus) Correction



NATIONAL ASSOCIATION FOR THE BLIND (INDIA)



Promoting the interests of people with vision loss in India

Particular	Total Commitment
Corneal Transplant Surgeries	200
Squint Correction Surgeries	40
Educational Braille Kits	295
Grant for Diploma in Special Education (D'ED) course	1



Educational Braille Kit

India Pharma Awards 2018 on 12th December 2018

Excellence in CSR



Excellence in Export Promotion



Pharma International Excellence



Great Place To Work[®] Certified



Insights Success Magazine – April 2019



Hindustan Times Thane Ratna Award on 31st January 2019



World HRD Congress 2018 on 16th February 2019

National Best Employer Brand



Business Leader of the Year



Top 101 HR Minds



Pride of Maharashtra: Best CEO of the Year 21st February 2019





Contact Us

Company :



CIN No: L99999MH1951PLC008485

Mr. Sumesh Gandhi
sumesh.gandhi@dil.net

www.dil.net

Investor Relations Advisors :



CIN - U74140MH2010PTC204285

Mr. Jigar Kavaia
jigar.kavaia@sgapl.net
+91 9920602034

www.sgapl.net